ANNUAL REPORT 2017–2018 CONTENTS REPORT FROM THE BOARD CHAIR AND CHIEF EXECUTIVE ..............................................................7 BOARD OF DIRECTORS .............................................................17 PETER MAC SERVICES ............................................................ 20 ATTESTATIONS .......................................................................... 22 OTHER INFORMATION AND DISCLOSURES ......................... 24 SUMMARY OF FINANCIAL RESULTS ..................................... 28 EMPLOYMENT AND CONDUCT PRINCIPLES ........................ 30 ADDITIONAL INFORMATION AVAILABLE ON REQUEST ........................................................ 33 OBJECTIVES, FUNCTIONS, POWERS AND DUTIES ............................................................................... 34 2017-2018 STATEMENT OF PRIORITIES ............................... 35 DISCLOSURE INDEX ................................................................. 46 BOARD MEMBER’S, ACCOUNTABLE OFFICER’S AND CHIEF FINANCE AND ACCOUNTING OFFICER’S DECLARATION ............................. 48 FINANCIAL STATEMENTS ........................................................51 APPENDIX ................................................................................ 130 BREAKING NEW GROUND. CHANGING LIVES. “We are a cancer centre unsurpassed in the world, where humanity, caring service and relentless research share equal value. Nothing but the best is good enough in the treatment of cancer.” — Peter MacCallum 4. Vision and Values VISION VALUES To provide the best in cancer Excellence – ensuring that clinical care, accelerating discovery and practice is evidence-based and translating to cures. patient-centred and is provided by qualified and experienced staff who Peter Mac is a proud, mission- are accountable and appropriately driven organisation that leads on a credentialed. global scale. Our founder, Sir Peter MacCallum said: Innovation – fostered by supporting research and a learning culture. “We are a cancer centre unsurpassed in the world, where humanity, caring Compassion – adhering to the service and relentless research share strongest ethical standards to equal value. ensure a culture of openness, mutual respect and trust is at our core. Nothing but the best is good enough in the treatment of cancer.” Although he made that statement nearly 70 years ago, as a guiding principle it is as clear, simple and relevant today as when Sir Peter first said it. Peter MacCallum Cancer Centre Annual Report 2017-18 5. Achievements 300,000 600 $380M cancer research articles published in hospital treatments prestigious journals budget 225 41 5 active clinical research sites across trials laboratories Victoria 160,000+ $80M specialist clinic research budget appointments We treated 36,500+ research revenue from all sources reached patients, $80 MILLION 4% an increase in 2 years of more than 2016-17. 34% 9.4% INCREASE in surgical patients treated from the previous year 6. REPORT FROM THE BOARD CHAIR AND CHIEF EXECUTIVE. The year 2017-18 has been Last year, our 2,398 clinicians, outstanding for Peter MacCallum nurses, researchers, scientists, Cancer Centre. administrators and volunteers – delivered services from our home in We are, very proudly, Australia’s the Victorian Comprehensive Cancer only public hospital solely dedicated Centre (VCCC) building in Parkville to cancer treatment, research and and at our sites in Bendigo, Box education. Hill, Moorabbin and Sunshine, and Peter Mac delivers high quality care throughout the broader community. and treatment for individual patients, Guided by our Strategic Directions and improves the health and 2015-2019, we are closer than ever wellbeing for all Victorians affected to achieving our goal to be one of the by cancer. We achieve this through a top ten cancer hospitals in the world. comprehensive, globally-recognised cancer research program, our During 2017-18, we made significant network of international and national progress against our four Strategic partners, as well as world-class Directions, supported by a series of training of current and future health four Strategic Enablers. professionals. The Hon. Maxine Morand Ms Dale Fisher Chair, Board of Directors Chief Executive Peter MacCallum Cancer Centre Annual Report 2017-18 7. Report from the Board Chair and Chief Executive STRATEGIC DIRECTION: Provide the world’s best cancer care In 2017-18, Peter Mac cared for Our eight-bed short stay (23 more cancer patients than any other hour) unit for patients, who need Australian hospital. monitoring post-surgery but do not require an overnight bed, has According to the Victorian Healthcare successfully freed up in patient Experience Survey (VHES), beds, improving bed utilisation and perceptions of our care are very increasing flow through surgery. positive – 99% of adult Inpatients and As a result we treated an additional 98% of adult specialist clinic patients 469 surgical patients during the year, rated their overall experience as a 9.4% increase in surgical patients ‘very good’ or ‘good’. Our performance treated from the previous year. on a range of other key indicators remained above the We pride ourselves on caring for our We are frequently the benchmarked peer patients, not only during their stays average. with us, but after they return to their first site in Australia lives. We do this in a myriad of ways: Treatment for our to recruit patients for patients begins • the introduction of a nurse-led international first-in- with research. survivorship clinic in breast Clinical trials are cancer means that patients, human clinical trials. the foundation for the first time, are given upon which clinical a survivorship care plan at medicine is practised and patient discharge, which is then followed outcomes are realised. up in a shared care model with their GP. This initiative increases There are 225 clinical trials active at GP capacity and saves time in our Peter Mac at any one time. We are busy clinics by ensuring patients frequently the first site in Australia who need support get it directly. to recruit patients for international first-in-human clinical trials. Trials • the introduction of telehealth commonly involve new cancer consultations in 2017. Through therapeutics but also examine new telehealth, patients can have an approaches to surgery, radiation appointment with their Peter therapy, supportive care, pain control Mac specialist by video from and better ways of detecting the their home, with their local GP or spread of tumours. from their local health service. Our telehealth consultations During the year, we increased expanded last year and were clinical trial access by flexing-up conducted by 50 clinicians from four additional beds in the Parkville around Victoria for approximately Cancer Clinical Trials Unit. This 55 patients per month. means we can provide increased, more intense monitoring for clinical trial patients with trained nurses, while also freeing up inpatient beds. 8. Report from the Board Chair and Chief Executive STRATEGIC DIRECTION: Accelerate discovery and translational research Underpinned by internationally In the last two years, we have recognised clinical and laboratory established three global industry research staff and world’s best collaborations with pharmaceutical facilities, Peter Mac leads the way companies, Roche-Genentech, in the translation of research in the Bristol-Myers Squibb and Glaxo- prevention, diagnosis, treatment and Smith-Kline, to support lab-based care of cancer patients. and translational research in cancer immunotherapy. In addition to Peter Mac has 580+ full time providing more than $10 million in researchers funded from peer- additional funding for Peter Mac- review, industry and philanthropic led translational studies, these sources. In 2017-18, research international networks include world revenue from all sources reached renowned academic institutions $80 million, an increase of 34% in (Memorial Sloan Kettering, Institute just two years. Of this funding, we Gustave Roussey, Netherlands received $26.4 million from the Cancer Institute) that now formally National Health Medical Research align us with the very best like- Council organisations on the global stage. Peter Mac leads the (NHMRC). Recently, Peter Mac was invited Peter Mac way in translation of to join a selected number of continues a elite organisations in becoming research in the prevention, strategy of a Milner Therapeutics Institute promoting diagnosis, treatment and Affiliated Organisation. The Milner and investing Therapeutics Institute is part of the care of cancer patients. in the highly University of Cambridge. Its mission educated and is to accelerate academic research specialised discipline of clinician towards medical advancement by researchers. We employ the largest connecting the research potential number of PhD students – who of the University of Cambridge and are clinicians – in Australia and its affiliated organisations with the we intend to further bolster these drug development expertise and numbers. Clinician researchers are resources of the pharmaceutical key to driving translational research. industry. Many of our labs that carry out These international partners offer discovery-based fundamental a range of potential benefits to and translational research are led Peter Mac, including attracting by qualified medical specialists, talent, building capability, furthering particularly medical oncologists. training and education, establishing This is an important distinction